Aquilo Capital Management, LLC Protagonist Therapeutics, Inc Transaction History
Aquilo Capital Management, LLC
- $64.3 Million
- Q4 2024
A detailed history of Aquilo Capital Management, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Aquilo Capital Management, LLC holds 76,592 shares of PTGX stock, worth $2.89 Million. This represents 4.6% of its overall portfolio holdings.
Number of Shares
76,592Holding current value
$2.89 Million% of portfolio
4.6%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
254Shares Held
58.9MCall Options Held
226KPut Options Held
218K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$224 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$217 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$208 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$159 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$126 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.85B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...